{
    "nctId": "NCT01796197",
    "briefTitle": "Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa",
    "officialTitle": "Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 23,
    "primaryOutcomeMeasure": "Percentages of Participants With Pathologic Complete Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed invasive breast cancer\n* HER2 positive breast cancer\n* Clinical diagnosis of inflammatory breast cancer\n* Without evidence of visceral or bone involvement with metastatic cancer on physical exam or any diagnostic study. Extensive nodal involvement is allowed\n* Willingness to undergo a research biopsy of the affected breast\n\nExclusion Criteria:\n\n* Prior therapy for the treatment of breast cancer\n* Receiving any other investigational or commercial agents or therapies\n* Known brain metastases\n* Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel, trastuzumab, pertuzumab\n* Uncontrolled intercurrent illness\n* Pregnant or breastfeeding\n* History of a different malignancy except for the following circumstances: disease-free for at least 5 years and at low risk of recurrence, or cervical cancer in situ or basal or squamous cell carcinoma of the skin\n* HIV positive on combination anti-retroviral therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}